Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.
Suswam EA, Shacka JJ, Walker K, Lu L, Li X, Si Y, Zhang X, Zheng L, Nabors LB, Cao H, King PH. Suswam EA, et al. Among authors: nabors lb. J Neurooncol. 2013 Jun;113(2):195-205. doi: 10.1007/s11060-013-1112-8. Epub 2013 Mar 25. J Neurooncol. 2013. PMID: 23525947 Free PMC article.
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium. Reardon DA, et al. Among authors: nabors lb. Neuro Oncol. 2015 Mar;17(3):430-9. doi: 10.1093/neuonc/nou160. Epub 2014 Aug 19. Neuro Oncol. 2015. PMID: 25140039 Free PMC article. Clinical Trial.
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA. Nabors LB, et al. Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11. Neuro Oncol. 2015. PMID: 25762461 Free PMC article. Clinical Trial.
Complementary therapy and survival in glioblastoma.
Mulpur BH, Nabors LB, Thompson RC, Olson JJ, LaRocca RV, Thompson Z, Egan KM. Mulpur BH, et al. Among authors: nabors lb. Neurooncol Pract. 2015 Sep;2(3):122-126. doi: 10.1093/nop/npv008. Epub 2015 May 6. Neurooncol Pract. 2015. PMID: 26649185 Free PMC article.
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Holdhoff M, et al. Among authors: nabors lb. Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020. Neuro Oncol. 2017. PMID: 28371832 Free PMC article. Clinical Trial.
178 results